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Abstract
Background: The daily use of Trimethoprim-Sulfamethoxazole (TMP-SMX) prophylaxis reduces morbidity and mortality among
patients infected with human immunodeficiency virus (HIV) but its impact on increasing antimicrobial resistance rates has been of
public health concern, globally. This study investigated the effect of daily TMP-SMX prophylaxis on feacal carriage rates of
resistant isolates of Escherichia coli in HIV-infected adult patients in Lagos.
Methods: A total of 550 HIV-infected patients with CD4-cell counts of less than 350 cells/mm3 who were eligible for TMP-SMX
prophylaxis and attending Lagos University Teaching Hospital, Lagos, Nigeria, were recruited for this study. Stool/rectal swab
samples were aseptically collected from the patients and processed using standard methods for culture and sensitivity.
Results: There was a baseline Trimethoprim-Sulfamethoxazole resistance rate of 54% which increased to 77.9% in first 3 months,
rising to 96.1% by 6 months and all isolates were resistant by the 9th month. There was also evidence of cross-resistance to other
antibiotics with significance in association with TMP-SMX resistance (p<0.0001). The Escherichia coli isolates showed a
progressive increase in resistance to the tested antibiotics over the 12-month period. The resistance was in the following order:
Ampicillin (74% to 82.6% in the first 3 months; 98.3% by the 6th month and 99.4% by the 9th month; all isolates were resistant by
the 12th month), Augmentin (32.5% to 47.7% in first 3 months; 76.1% by the 6th month; 86.3% by the 9th month; all isolates were
resistant by 12 months), Ceftriaxone (2.0% to 10.8% in first 3 months; 20.6% by the 6th month; 24.2% by the 9th month; 54.3% by
the 12 months).
Conclusions: The carriage rate of feacal E. coli resistant to TMP-SMX is common before TMP-SMX prophylaxis. Initiation of
TMP-SMX leads to further increase in resistance to TMP-SMX and cross-resistance to other antimicrobials.
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Introduction
Human immunodeficiency virus (HIV) infected patients are at increased risk of opportunistic infections including serious
bacterial infections mainly due to Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus pneumoniae, and
Enterobacteriaceae. In sub-Saharan Africa, these infections account for over 90% of morbidity and mortality found in these patients
(WHO, 2006). However, the conference convened by the Joint United Nations Program on HIV/AIDS (UNAIDS) and the World
Health Organization in April 2000 recommended that Trimethoprim-Sulfamethoxazole (septrin) be used for prophylaxis in adults
and children living with HIV/AIDS in Africa as part of a minimum package of care for the prevention of opportunistic infections
including most bacterial, parasitic and protozoal infections especially Pneumocystis carrinii pneumonia (PCP) which is the most
common presenting manifestation in Africa (UNAIDS/WHO, 2000).
This recommendation was based on the evidence from trials on Trimethoprim-Sulfamethoxazole prophylaxis conducted in
African countries including: Cote d’Ivoire, South Africa, Malawi, Zambia, and Uganda which showed significant reductions in
mortality of between 25% and 46% morbidity. This effect was also significant even in areas with high bacterial acquired resistance
(Werarak et al., 2006; Grimwade et al., 2005). This resulted in decreased frequency of clinic visits and hospitalizations. Other
studies carried out in Uganda and Zambia showed a beneficial effect of Trimethoprim-Sulfamethoxazole prophylaxis on CD4 cell
count and HIV viral load (Mermin et al., 2004; Chintu et al., 2004). In addition, it is inexpensive, readily available and relatively
safe (Grimwade and Gilks, 2001; Castebon et al., 2001). Septrin and the related compound sulfadoxine-pyrimethamine play central
roles in the management of common clinical syndromes in Africa. These drugs are frequently used to treat dysentery, lower
respiratory tract infection, and fever in which Shigella spp., non-Typhi serotypes of Salmonella enterica, Streptococcus pneumoniae,
and Plasmodium spp., respectively, play major roles. It follows that increases in resistance to septrin among these pathogens could
reduce the effectiveness of empirical treatment strategies, leading to more illness and death. Therefore concern was raised that
widespread use of SXT may substantially increase the prevalence of antimicrobial resistance in common community-acquired
pathogens.
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Continuous exposure of bacteria to antibiotics leads to antibiotic resistance from selective pressure. Trimethoprim-
Sulfamethoxazole prophylaxis creates such a selection pressure (Cotton et al., 2008) on Escherichia coli which is a normal
commensal in the gastrointestinal tract (GIT) of humans. Large microbial population in the GIT (over 109/ml of feaces) allow for
easy transmission of antimicrobial resistant elements between various organisms and E. coli has been shown to be a source of
resistant gene to Salmonella, Shigella, Yersina, and Vibrio species as well as potentially pathogenic Escherichia coli (Chiller et al.,
2003; Chikwendu et al., 2008). We therefore decided to evaluate the impact of Trimethoprim-Sulfamethoxazole prophylaxis on
antimicrobial resistance using Escherichia coli as an indicator.
Materials and Methods
Study Area and Population
The study was carried out in the Adult HIV Clinics of the Lagos University Teaching Hospital (LUTH) and the National
Institute for Medical Research (NIMR), Yaba both in Nigeria.
Study Design
The study was an incidence and a cross-sectional study.
Cross-sectional study:
This was carried out over a 3 month period between February and April 2009 at the Adult HIV Clinics in LUTH Idi-araba
and NIMR Yaba, Lagos. A total of 550 (82.2%) participants out of the 669 patients that were diagnosed with HIV in that period
were recruited. Using the clinic register, every second patient that consented was recruited. Of these 600 participants, 200 patients
registered newly at the period of recruitment (0 month) while four groups each comprising 100 patients were at their 3th, 6th, 9th and
12th month hospital visit.
Incidence study:
The 200 (20%) newly registered patients who had not commenced TMP-SMX prophylaxis out of the 2012 patients
attending the clinic that year were randomly recruited and followed up for a period of one year on outpatient basis. Also 120
participants who were not on TMP-SMX prophylaxis were recruited and followed up for one year as control. These were siblings or
spouses of the HIV-infected patients who regularly accompanied them to the clinic. They were HIV-negative and not on TMP-SMX.
Ethical Consideration:
The study was reviewed and approved by the Research and Ethics Committee of the Lagos University Teaching Hospital
according to Helsinki Declaration. All patients were required to sign an informed consent and those that gave their consent were
recruited. Samples, data and results of patients were treated with utmost confidentiality and used for the purpose of this study only.
Sample collection
Stool samples were collected in sterile universal bottles. Three rectal swabs were collected from patients who could not
produce faeces. No patient was sampled more than once in the cross-sectional study while a repeat stool sample were collected from
all the new patients that were followed up as a cohort at their 3th, 6th, 9th and 12th month hospital visit. A two week window of
opportunity before and after the expected date of collection was accepted.
Stool and rectal swabs were immediately taken to the laboratory of the Department of Medical Microbiology and Parasitology of the
College of Medicine, University of Lagos, Nigeria, and processed within one hour of collection.
Isolation and Identification of Escherichia coli
Faecal samples were inoculated directly onto MacConkey agar (Oxoid) and incubated for 24 hours at 370C. From each
plate, three to five smooth, dry and flat colonies that were lactose fermenting were picked, and sub-cultured for purity. Pure colonies
were gram stained. If gram negative, a part of one colony was picked and tested for motility. If motile, a part of the same colony was
subcultured and tested for indole. All indole positive, motile gram negative bacilli were further characterized on the basis of their
reactions to citrate, oxidase, urease, and growth characteristics on Kliager Iron Agar. All motile gram-negative, oxidase and urea
negative, indole positive, producing acid in both the butt and slant on KIA with greenish metallic-sheen colonies on Eosin methylene
blue (EMB) agar were presumed to be E. coli. These isolates were then stored on nutrient agar (oxoid) slants for antibiotic
susceptibility testing.
Antimicrobial Susceptibility Testing
The antimicrobial susceptibility tests were carried out using Kirby-Bauer disk diffusion method as recommended by the
Clinical and Laboratory Standards Institute (CLSI, 2009). The antibiotics tested were: ceftriaxone (30µg), ciprofloxacin (5µg),
amoxicillin/clavulunate (20/10µg), gentamicin (10µg), ampicillin (10µg), imipenem (30µg) and trimethoprim-sulfamethoxazole
(1.25/23.75µg). Escherichia coli ATCC 25922 strain was used as a control.
All antibiotic discs were allowed to equilibrate to room temperature before use. Isolates with zones of inhibition to TMP-
SMX above 16mm were considered sensitive while those less than 10mm were considered resistant. The Minimum inhibitory
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concentrations (MIC) of these resistant isolates were carried out using Etest method to confirm resistance of these drugs in
accordance to the CLSI methodology (CLSI, 2009).
TMP-SMX resistant isolates were further screened for β-lactamase production using a nitrocephin disc. All isolates that 
were resistant to 3rd generation cephalosporin were tested for extended β-lactamase (ESBL) production (CLSI, 2009). ESBL was 
determined according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) by means of a double disk diffusion
method (CLSI, 2009).
Statistical analysis
The Epi-Info software 6.04 version (World Health Organization) was used for data analysis.
Results
Socio-Demographic Characteristics
A total of 550 were recruited into a cross sectional study and the effect of TMP-SMX prophylaxis on intestinal isolates of
E. coli evaluated at pre-TMP-SMX prophylaxis (0) and at the 3rd, 6th, 9th, and 12th month prophylaxis. The mean age of the
participants was 35.6 ± 9.1, about half (52%) were married while the male to female ratio was 1:1.4. All participants came from
socio-economically deprived settings with 18.2 % being Unemployed, 11.1 % Artisans and 11.6% Traders. The participant’s ability
to read and write was low; 40.4 % attended primary school, 43.4 % secondary school and 8.6% had no formal education. The
median income level was ₦6,500.00 per month, with on average of 5 persons per household, translating     into ₦217.00/person/day. 
Nine (1.6%) patients were hospitalized within the last three months, 28 (5.1%) took over-the-counter antimicrobials in the preceding
month, and 17 (3.1%) took herbal medications within the last three months.
Among the controls, the mean age was 34.9 ± 4. 57.5% were married while the male to female ratio was 1:1.6. Also all
participants came from socio-economically deprived settings with 14.2 % being Unemployed, 12.5 % Artisans, and 17.5% were
Traders. The participant’s ability to read and write was low; 34.0 % attended primary school, 51.0% secondary school and 7.0% had
no formal education.
The median income level was ₦6,250.00 per month, with on average of 5 persons per household, translating into 
₦208.00/person/day. Sixty-two (11.3%) took over-the-counter antimicrobials in the preceding month, and 34 (6.2%) took herbal 
medications within the last three months.
Cross Sectional Study
Carriage rate of TMP-SMX resistance of feacal Escherichia coli.
The carriage rate of TMP-SMX resistant isolates of E. coli varied between the different groups of patients. One hundred
and eight (54%) of the 200 isolates (0 month) were resistant. And in each of 100 participants, 80% of the isolates were resistant at 3
month visit, 97% at 6 month visit, 99% at 9 month visit, and 100% at 12 month visit (Figure 1). There was an increasing trend in
TMP-SMX resistance among each group of patients. However, there is statistically significant difference between TMP-SMX
resistance at 3 months and that of 0 month (p=0.001) and also between TMP-SMX resistance at 6 months and that of 3 months
(p=0.001). There was no statistical difference between TMP-SMX resistance at 9 months and 6 months (p=0.07) as well as between
12 months and 9 months.
TMP-SMX resistance and antibiotic resistance profile.
Co-selection of antimicrobial resistance was assessed among all the isolates. With the commencement of TMP-SMX
prophylaxis, TMP-SMX resistance was found to be strongly associated with cross resistance to all other antimicrobial tested except
Imipenem (Figure 2) (p<0.000001).
Risk factors for Acquisition of TMP-SMX Resistance.
Multivariate logistics was done which showed that the use of Ampiclox and Sulfadoxine-pyrimethamine at the preceding
month predict TMP-SMX resistance (OR 8.05, CI 1.78-36.49, p< 0.007) and (OR 12.14, CI 1.53-96.07, p<0.018) respectively. This
was irrespective of the patients̕̕ educational or income level, occupation, length of hospital stay, intake of herbal medicine and
acquisition of either β-lactamase or extended spectrum β-lactamses (ESBL). 
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Figure 1: Carriage rate of resistant E. coli among the various groups of patients.
Figure 2: Association of TMP-SMX resistance and antibiotic resistance profile.
Cohort Study
Of the 200 patients recruited, loss to follow-up occurred in both the study participants and the control. Five (2.5%) were
lost at three month visit, 15(7.7%) at six month, 19 (10.5%) at nine month, and 10(6.6%) at twelve month visit. Of the 120 controls
recruited, 1 (0.8%) was lost at three month visit, 8 (6.7%) at six month, and 11 (9.9%) at nine and none at twelve month visit.
Carriage rate of resistant Escherichia coli isolates due to TMP-SMX prophylaxis.
The carriage rate of TMP-SMX resistance varied at each hospital visit between the participants and the control.
Among the participants, the carriage rate of TMP-SMX resistant isolates was 108 (54.0%) at 0 month, 152 (77.9%) at 3 months, 173
(96.1%) at 6 months and 161 (100.0%) at 9 months, and 151(100%) at 12 months while that of the control was 35(29.2%) at 0
month, 33 (27.7%) at 3 months, 34 (30.6%) at 6 months and 51 (51.0%) at 9 months, and 53(53.0%) at 12 month Figure 3.The
difference in the increasing trend in TMP-SMX resistance and selection of TMP-SMX resistance among the participants were
because these patients were on TMP-SMX prophylaxis. However, there is statistically significant difference between TMP-SMX
resistance among the participants when compared with the control at each hospital visit starting from the baseline (p=0.001), at 3
months (p=0.0001), at 6 months (p=0.0001), at 9 months (p=0.001), and at 12 months (p=0.0001).
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Figure 3: Carriage rate of resistant Escherichia coli isolates due to TMP-SMX prophylaxis.
Effect of TMP-SMX prophylaxis on antibiotic resistance profile.
Co-selection of antimicrobial resistance due to TMP-SMX prophylaxis was also assessed among all the isolates from the
study participants in each hospital visit. The association of other antibiotics tested to septrin prophylaxis is shown in Figure 4. This
was found to be statistically significant. This revealed that the longer the patient stayed on TMP-SMX, the higher the chance of
developing resistance (p=0.0001).
Risk factors for Acquisition of Resistance.
Among the controls, there was a gradual increase in trend of TMP-SMX resistance (Figure 3). This increase was attributed
to the use of Ampiclox and Sulfadoxine-Pyrimethamine in the preceding month which was found to be strongly associated with
TMP-SMX resistance (OR 10.05, CI 1.92-36.49, p< 0.005) and (OR 11.04, CI 1.45-94.06, p<0.002) respectively. This was also
irrespective of the patients̕̕ educational or income level, occupation, length of hospital stay, intake of herbal medicine and acquisition
of either β-lactamase or extended spectrum β-lactamses (ESBL) (p≤ 0.0001).  
Figure 4: Effect of TMP-SMX prophylaxis on antibiotic resistance profile.
Effect of TMP-SMX prophylaxis on Acquisition of resistance.
The association of acquisition of resistance to TMP-SMX resistance is shown in Figure 5. This was also found to be
statistically significant among the participants group than the control (p=0.001). This revealed that the longer the patient is on TMP-
SMX, the higher chance of developing resistance.
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Figure 5: Effect of TMP-SMX prophylaxis and Acquisition of resistance.
Comparison of the carriage rate and the effect of TMP-SMX prophylaxis between cross sectional and cohort study.
In both studies, it was shown clearly that there was increasing trend in carriage rate of resistant E. coli isolates (Table1).
There was also an increasing trend in resistance between TMP-SMX prophylaxis and other antibiotics tested (Table 2). These
validate the hypothesis that initiation of TMP-SMX prophylaxis in HIV-infected individuals would lead to rapid and widespread
resistance of feacal E. coli to TMP-SMX.
Table 1: Carriage rate of resistant Escherichia coli isolates due to TMP-SMX prophylaxis.
Months of
follow up
Resistance Carriage rate
Cross sectional Study Control Study
N Freq % Case Control
N Freq % N Freq %
0 200 108 54.0 200 108 54.0 120 35 29.2
3 100 89 89.0 195 152 77.9 119 33 27.7
6 100 97 97.0 180 173 96.1 111 34 30.6
9 100 99 99.0 161 161 100 100 51 51.0
12 100 99 99.0 151 151 100 100 53 53.0
N = total number
Table 2: The Effect of septrin prophylaxis on antibiotic resistance profile.
Antibiotics tested % Resistance
Cross sectional study Cohort study
0 3 6 9 12 0 3 6 9 12
Ampicillin 74.0 97.7 100.0 94.9 99.1 74.0 82.6 98.3 99.4 100.0
Augmentin 32.5 56.8 75.0 85.9 87.0 32.5 47.7 76.1 86.3 100.0
Ceftriaxone 2.0 2.3 4.0 4.0 24.0 2.0 10.8 20.6 24.2 54.3
Genticin 7.5 25.0 33.0 35.4 61.0 7.5 6.2 13.9 22.4 32.5
Ciprofloxacin 12.0 20.5 52.0 60.6 82.0 12.0 17.9 26.7 62.1 82.1
Imipenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Discussion
The effect of TMP-SMX prophylaxis on fecal carriage rates of resistant E. coli was studied to assess the role of TMP-
SMX in driving antimicrobial resistance. The carriage rate of TMP-SMX resistant E. coli even before the commencement of TMP-
SMX prophylaxis was 54%. This was similar with the recent observational cohort study done in Moshi, Tanzania on the effect of
TMP-SMX prophylaxis on antimicrobial resistance of feacal Escherichia coli in HIV- infected patients. Out of fifty-seven (57)
feacal E. coli isolated from HIV-infected patients that were on TMP-SMX prophylaxis, 37(64.9%) were already resistant to TMP-
SMX before the commencement of TMP-SMX prophylaxis (Zachariah et al., 2002). Studies in East Africa and southern Africa have
also demonstrated such resistance in Enterobacteriaceae (van Oosterhout et al., 2005; Murray, 1987; WHO, 2007). Concern about
the impact of TMP-SMX resistance among key HIV bacterial co-pathogens on the efficacy of TMP-SMX prophylaxis has been
raised (Murray and Rensimer, 1983). Although large observational studies carried out in East Africa and southern Africa have shown
that TMP-SMX prophylaxis significantly reduces morbidity and mortality, even in settings where TMP-SMX prophylaxis is more
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common (Mwaungulu et al., 2004; Buskin et al., 1999), no study has investigated the magnitude of the effect of TMP-SMX
prophylaxis on resistance pattern of intestinal feacal flora.
In this study, most of the patients on TMP-SMX prophylaxis continued to carry TMP-SMX resistant E. coli at a proportion
higher than baseline. Furthermore, initiation of TMP-SMX prophylaxis rapidly leads to further loss of susceptibility not only to
TMP-SMX but to other important antimicrobial agents. This finding suggests that the impact of TMP-SMX prophylaxis on
antimicrobial resistance of bacterial flora occurs rapidly and that it is sustained as long as TMP-SMX prophylaxis is continued.
Although only the feacal indicator organism E. coli was studied there also is evidence from East Africa that antimicrobial use is
associated with the frequency of resistance among bacterial enteric pathogens. In Kenya, resistance to antimicrobials among
diarrheal non-Typhi Salmonella and Shigella spp. was inversely proportional to the frequency with which the antimicrobials were
prescribed, with TMP-SMX being the most common treatment prescription and the least effective agent (Mermin et al., 2005a).
We demonstrated that the initiation of TMP-SMX prophylaxis not only selects for TMP-SMX resistant E. coli but also seems to
select for ampicillin, augmentin, ceftriaxone, genticin, and ciprofloxacin resistant E. coli. It is likely that a mechanism for the
coselection of resistance is by means of mobile genetic elements such as integrons in plasmids and transposons. Research on
enteroinvasive or enteroaggregative E. coli in Senegal showed that trimethoprim and other antimicrobial resistance was common and
that the mechanism was likely within the class 1 integron-containing plasmids that may be horizontally transferred from gut
commensal organisms (Hall and Collis, 1995; Gassama et al., 2004). In Tanzania, a study examining prevalence and mechanisms of
antimicrobial resistance among Shigella spp. from paediatric stool cultures found that resistance to ampicillin, chloramphenicol,
tetracycline, and TMP-SMX was common (Navia et al., 1999). Ampicillin resistance was most frequently related to an integron-
borne OXA-1-type b-lactamase, and resistance to TMP-SMX was attributable to the presence of an integron-borne dhfr Ia gene
(Gassama et al., 2004). Studies in Europe and Canada on uropathogenic E. coli that was resistant to trimethoprim, sulfamethoxazole,
or both found dfr or sul gene-containing integrons in 59% of isolates. Analysis of the regional distribution of these integrons
indicated that horizontal gene transfer was the main mechanism of resistance spread rather than clonal expansion (Murray and
Rensimer, 1983). These studies suggest that coselection of resistance by means of mobile genetic elements in fecal E. coli
attributable to TMP-SMX use is likely to occur and that these genetic elements can disseminate from feacal flora to bacterial enteric
pathogens. This study also revealed that among the control group (those who were not on TMP-SMX prophylaxis), gradual increase
in trend of TMP-SMX resistance was seen over time (Figure 4). This is in contrast to the study by Mermin et al. in Uganda which
showed that antimicrobial resistance among diaorrheal pathogens infecting family members did not increase (Mermin et al., 2005b).
This increase was attributed to the use of Ampiclox and Sulfadoxine-Pyrimethamine in the preceding month. This is due to abuse
and misuse of these antibiotics which are readily available at every patent medicine store of the country and are readily given out to
these patients by these unqualified medical personnel (Okeke et al., 1999). This study demonstrated that the carriage rate of fecal E.
coli resistant to TMP-SMX is common among HIV patients before the commencement of TMP-SMX prophylaxis. The carriage rate
went from 54% at baseline to 99% and 100% after one year in cross-sectional and cohort study respectively. This study also revealed
that septrin prophylaxis induces an accelerated selection of multi-drug resistant strains and co-selection to other antibiotic classes as
well (ampicllin, augmentin, ceftriaxone, ciprofloxacin, and genticin). Finally, the use of Ampiclox and Sulfadoxine-Pyrimethamine
in the preceding month was found to predict Trimethoprim-Sulfamethoxazole resistance among both case and control groups. This
was irrespective of other risk factors like the patients̕̕ educational or income level, occupation, length of hospital stay, intake of 
herbal medicine and acquisition of either β-lactamase or extended spectrum β-lactamses (ESBL).  
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